<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02820155</url>
  </required_header>
  <id_info>
    <org_study_id>201412002MIPD</org_study_id>
    <nct_id>NCT02820155</nct_id>
  </id_info>
  <brief_title>Phase I Single and Multiple Escalating Dose Study of RGN1016 in Healthy Male Subjects</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled, Dose-Escalating, Single Dose and Multiple Dose Study to Evaluate the Safety and Pharmacokinetics of RGN1016 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Taiwan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, randomized, placebo-controlled, dose-escalating, single dose and
      multiple dose study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, randomized, placebo-controlled, dose-escalating study. The study
      comprises single dose (Stage I) and multiple dose (Stage II) stages. Stage II will not be
      initiated until completion of Stage I. The interim safety analysis report will be submitted
      to TFDA for an approval for proceeding to Stage II.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of incidence of Adverse Events.</measure>
    <time_frame>up to14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>8 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to peak drug concentration (Tmax)</measure>
    <time_frame>8 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>8 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life T1/2</measure>
    <time_frame>8 days</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RGN1016_50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RGN1016_100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RGN1016_200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RGN1016_400mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RGN1016_800mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RGN1016</intervention_name>
    <description>Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)</description>
    <arm_group_label>RGN1016_50mg</arm_group_label>
    <arm_group_label>RGN1016_100mg</arm_group_label>
    <arm_group_label>RGN1016_200mg</arm_group_label>
    <arm_group_label>RGN1016_400mg</arm_group_label>
    <arm_group_label>RGN1016_800mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects may be entered in the study only if they meet all of the following criteria:

          1. Male with suitable veins for cannulation or repeated venipuncture, and must be able to
             swallow the study drug intact;

          2. Aged between 20 and 45 years (inclusive) at the screening visit;

          3. Has normal hematology results at screening visit;

               -  WBC: 3.54 ~ 9.06X10^3/μL

               -  RBC: 4 ~ 5.52X10^6/μL

               -  hemoglobin: 13.2 ~17.2 g/dL

               -  hematocrit: 40.4 ~ 51.1%

               -  platelet: 148 ~ 339X10^3/μL

          4. Has normal biochemistry results at screening visit;

               -  alkaline phosphatase: 34 ~ 104 U/L

               -  total bilirubin: 0.3 ~ 1.0 mg/dL

               -  AST: 8 ~ 31 U/L

               -  ALT: 0 ~ 41 U/L

               -  BUN: 7 ~ 25 mg/dL

               -  creatinine: 0.6 ~ 1.3 mg/dL

          5. Normal coagulation results at screening visit;

               -  Prothrombin time/INR: 9.8 ~ 11.5 sec/0.92 ~ 1.09

               -  PTT: 25.6~32.6 sec

          6. Normal blood pressure (systolic blood pressure: 100 ~ 140 mmHg; diastolic blood
             pressure: 60 ~ 90 mmHg) at screening visit or prior to administration of
             investigational product;

          7. Able to provide written informed consent and willing to comply with the study protocol
             procedures and restrictions.

        Exclusion Criteria:

        Subjects must not satisfy any of the following criteria:

          1. Has a body weight less than 50 kg and/or body mass index (BMI) less than 18 kg/m^2 or
             greater than 30 kg/m^2 at the screening visit. Body mass index is determined as total
             body weight/height^2 (kg/m^2);

          2. Is not in good general health as judged by the Investigator based on medical history,
             vital signs, physical examination, ECG, laboratory tests, and urinalysis at the
             screening visit or prior to administration of investigational product;

          3. Has a history or presence of any disease or condition known to interfere with the
             absorption, distribution, metabolism, or excretion of drugs at the screening visit or
             prior to administration of investigational product;

          4. Has a clinically significant psychiatric, renal, hepatic, cardiovascular,
             gastrointestinal, or neurologic disease at screening or prior to administration of
             investigational product;

          5. Is a smoker and/or has used nicotine-containing products within the last 6 months
             prior to the screening visit;

          6. Has a history of alcohol and/or drug abuse;

          7. Participation of any clinical investigation during the last 60 days;

          8. Blood donation of more than 250 mL within the past 12 weeks;

          9. Excessive intake of caffeine containing drinks or food (more than 6 units of caffeine
             per day). One caffeine unit is contained in the following items: 1 (177.4 mL) cup of
             coffee, 2 (354.9 mL) cans of cola, 1 (354.9 mL) cup of tea, ½ (118.3 mL) cup of energy
             drink (e.g., PAOLYTA B Liq. or WHISBIH Liq.) or 3 oz of chocolate;

         10. Use of drugs with enzyme inducing properties such as St. John's Wort within 4 weeks
             prior to dosing;

         11. Has used prescription or nonprescription medication (except for occasional use of
             paracetamol and nasal spray) or herbal remedies or vitamins or minerals within 2 weeks
             or 5 half-lives of the drug, whichever is longer, prior to dosing;

         12. Any intake of grapefruit, grapefruit juice, Seville oranges, Seville orange marmalade,
             or other products containing grapefruit or Seville oranges within 7 days of the first
             administration of study medication;

         13. Male subjects who are unwilling to use barrier contraception in addition to having
             their partner use another method of contraception, for the duration of the study and
             for 3 months after dosing;

         14. Has a positive result on screening for serum hepatitis B surface antigen (HBsAg),
             hepatitis C antibody (HCV Ab), or human immunodeficiency virus (HIV);

         15. Has received a blood transfusion within the last 6 months at screening;

         16. Involved in the planning or conduct of the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming-Jang Chiu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurology department of National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ming-Jang Chiu</last_name>
    <phone>+886-2-2312-3456</phone>
    <phone_ext>65339</phone_ext>
    <email>mjchiu@ntu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming-Jang Chiu</last_name>
      <phone>+886-2-2312-3456</phone>
      <phone_ext>65339</phone_ext>
      <email>mjchiu@ntu.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2016</study_first_submitted>
  <study_first_submitted_qc>June 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2016</study_first_posted>
  <last_update_submitted>July 5, 2016</last_update_submitted>
  <last_update_submitted_qc>July 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's disease,cognitive function</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

